Radius Drug Patent Portfolio
Radius owns 2 orange book drugs protected by 12 US patents Given below is the list of Radius's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11255842 | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog | 10 Jan, 2040 | Active |
| US11680942 | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) analog | 10 Jan, 2040 | Active |
| US10996208 | Abaloparatide formulations and methods of testing, storing, modifying, and using same | 30 Apr, 2038 | Active |
| US11782041 | Abaloparatide formulations and methods of testing, storing, modifying, and using same | 30 Apr, 2038 | Active |
| US11977067 | Abaloparatide formulations and methods of testing, storing, modifying, and using same | 30 Apr, 2038 | Active |
| US9592195 | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics | 05 Dec, 2031 | Active |
| US7803770 | Method of treating osteoporosis comprising administration of PTHrP analog | 28 Apr, 2031 | Active |
| USRE49444 | Method of treating osteoporosis comprising administration of PTHrP analog | 28 Apr, 2031 | Active |
| US8148333 | Stable composition comprising a PTHrP analogue | 08 Nov, 2027 | Active |
| US8748382 | Method of drug delivery for bone anabolic protein | 03 Oct, 2027 | Active |
| US7488496 | Effervescent compositions comprising bisphosphonates and methods related thereto | 11 Aug, 2023 | Expired |
| US7964212 | Effervescent compositions comprising phosphonates and methods related thereto | 06 Mar, 2023 | Expired |
Latest Legal Activities on Radius's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Radius.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 02 Apr, 2024 | US9592195 |
|
Email Notification
Critical
| 11 Oct, 2023 | US11782041 |
|
Recordation of Patent Grant Mailed
Critical
| 10 Oct, 2023 | US11782041 |
| Mail Patent eGrant Notification | 10 Oct, 2023 | US11782041 |
| Recordation of Patent eGrant | 10 Oct, 2023 | US11782041 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 10 Oct, 2023 | US11782041 |
| Sequence Moved to Public Database | 10 Oct, 2023 | US11782041 |
| Patent eGrant Notification | 10 Oct, 2023 | US11782041 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 03 Oct, 2023 | US8148333 |
|
Email Notification
Critical
| 21 Sep, 2023 | US11782041 |
|
Issue Notification Mailed
Critical
| 20 Sep, 2023 | US11782041 |
|
Email Notification
Critical
| 14 Sep, 2023 | US11782041 |
| Mail Pet Dec Routed to ODM (PUBS) | 13 Sep, 2023 | US11782041 |
|
Mail-Petition Decision - Dismissed
Critical
| 13 Sep, 2023 | US11782041 |
|
Petition Decision - Dismissed
Critical
| 12 Sep, 2023 | US11782041 |
Radius Drug Patents' Oppositions Filed in EPO
Radius drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 16, 2018, by Teva Pharmaceutical Industries Ltd. This opposition was filed on patent number EP15176548A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15176548A | Feb, 2018 | Isenbruck Bösl Hörschler LLP | Revoked |
| EP15176548A | Feb, 2018 | Teva Pharmaceutical Industries Ltd | Revoked |
Radius's Family Patents
Radius Drug List
Given below is the complete list of Radius's drugs and the patents protecting them.
1. Binosto
Binosto is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9592195 | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics |
05 Dec, 2031
(7 years from now)
| Active |
| US7488496 | Effervescent compositions comprising bisphosphonates and methods related thereto |
11 Aug, 2023
(1 year, 3 months ago)
| Expired |
| US7964212 | Effervescent compositions comprising phosphonates and methods related thereto |
06 Mar, 2023
(1 year, 8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Binosto's drug page
2. Tymlos
Tymlos is protected by 9 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11255842 | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog |
10 Jan, 2040
(15 years from now)
| Active |
| US11680942 | Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) analog |
10 Jan, 2040
(15 years from now)
| Active |
| US10996208 | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
30 Apr, 2038
(13 years from now)
| Active |
| US11782041 | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
30 Apr, 2038
(13 years from now)
| Active |
| US11977067 | Abaloparatide formulations and methods of testing, storing, modifying, and using same |
30 Apr, 2038
(13 years from now)
| Active |
| US7803770 | Method of treating osteoporosis comprising administration of PTHrP analog |
28 Apr, 2031
(6 years from now)
| Active |
| USRE49444 | Method of treating osteoporosis comprising administration of PTHrP analog |
28 Apr, 2031
(6 years from now)
| Active |
| US8148333 | Stable composition comprising a PTHrP analogue |
08 Nov, 2027
(2 years from now)
| Active |
| US8748382 | Method of drug delivery for bone anabolic protein |
03 Oct, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tymlos's drug page